1Q25 Wrap: Market backslide hits broad swath of companies

Large-cap biotechs narrowly avoided the downward trajectory of stock markets in 1Q25, treading water with a median gain of 1%. The group, defined as companies that started the year with market capitalizations of $5-$9.9 billion, saw 17 companies gain value and 16 lose value.

The other four market cap groups all posted a median loss...